Cold Agglutinin Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 02 18:57 2021
Cold Agglutinin Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
“Cold Agglutinin Disease (CAD) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cold Agglutinin Disease (CAD) market. A detailed picture of the Cold Agglutinin Disease (CAD) pipeline landscape is provided, which includes the disease overview and Cold Agglutinin Disease (CAD) treatment guidelines.

DelveInsight’s Cold Agglutinin Disease Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Cold Agglutinin Disease pipeline landscapes. It comprises Cold Agglutinin Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cold Agglutinin Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cold Agglutinin Disease pipeline products.     

Some of the key takeaways of the Cold Agglutinin Disease Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Sanofi, Apellis Pharmaceuticals, Janssen Pharmaceutical, etc., are developing therapies for the treatment of Cold Agglutinin Disease.

  • Emerging therapies such as Sutimlimab, APL-2, Bortezomib, are expected to have a significant impact on the  Cold Agglutinin Disease market in the coming years.

  • Currently, Sanofi is conducting the Phase III clinical trial of Sutimlimab for CAD and met the primary endpoints and secondary endpoints and demonstrated rapid inhibition of hemolysis. 

  • Apellis is currently testing APL-2 in Phase II and assessing the safety, tolerability, efficacy, and PK of multiple subcutaneous doses of APL-2. 

Get an overview of pipeline landscape @ Cold Agglutinin Disease Clinical Trials Analysis 

Cold agglutinin disease is an uncommon autoimmune hemolytic anaemia in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. 

Cold Agglutinin Disease Emerging Drugs

  • Sutimlimab by Sanofi

  • APL-2 by Apellis Pharmaceuticals

  • Bortezomib by Janssen Pharmaceutical

Scope of Cold Agglutinin Disease Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Sanofi, Apellis Pharmaceuticals, Janssen Pharmaceutical, and others.

  • Pipeline Therapies: Sutimlimab, APL-2, Bortezomib, and others.

Table of Contents


Cold Agglutinin Disease Report Introduction


Cold Agglutinin Disease Executive Summary


Cold Agglutinin Disease Overview


Cold Agglutinin Disease- Analytical Perspective In-depth Commercial Assessment


Cold Agglutinin Disease Pipeline Therapeutics


Cold Agglutinin Disease Late Stage Products (Phase II/III)


Cold Agglutinin Disease Mid Stage Products (Phase II)


Cold Agglutinin Disease Early Stage Products (Phase I)


Cold Agglutinin Disease Preclinical Stage Products


Cold Agglutinin Disease Therapeutics Assessment


Cold Agglutinin Disease Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Cold Agglutinin Disease Key Companies


Cold Agglutinin Disease Key Products


Cold Agglutinin Disease Unmet Needs


Cold Agglutinin Disease Market Drivers and Barriers


Cold Agglutinin Disease Future Perspectives and Conclusion


Cold Agglutinin Disease Analyst Views




About DelveInsight

Related Reports:

Cold Agglutinin Disease Market

DelveInsight’s Cold Agglutinin Disease – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cold Agglutinin Disease Epidemiology

DelveInsight’s Cold Agglutinin Disease – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Cold Agglutinin Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/ on line 7